-
Mashup Score: 0Learn more about VANFLYTA: A treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+ - 11 month(s) ago
Use the zip code search below to find a live location, or register to attend our upcoming broadcast virtually where we explore efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML.Find a live event near you!Please enter your ZIP codeCan’t make it to a live…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Learn more about VANFLYTA: A treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+ - 11 month(s) ago
Use the zip code search below to find a live location, or register to attend our upcoming broadcast virtually where we explore efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML.Find a live event near you!Please enter your ZIP codeCan’t make it to a live…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Join our upcoming broadcast to learn more about a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+. https://t.co/RlyqNmSMTM Review dosage, administration considerations, and drug interactions. Please see Full Prescribing Information… https://t.co/IBAMZzpqE8 https://t.co/eni3ZCtPtp
-
-
Mashup Score: 0Learn more about VANFLYTA: A treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+ - 11 month(s) ago
Use the zip code search below to find a live location, or register to attend our upcoming broadcast virtually where we explore efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML.Find a live event near you!Please enter your ZIP codeCan’t make it to a live…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Join our upcoming broadcast to learn more about a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+. https://t.co/RlyqNmSMTM Review dosage, administration considerations, and drug interactions. Please see Full Prescribing Information… https://t.co/IBAMZzpqE8 https://t.co/eni3ZCtPtp
-
-
Mashup Score: 0Learn more about VANFLYTA: A treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+ - 12 month(s) ago
Use the zip code search below to find a live location, or register to attend our upcoming broadcast virtually where we explore efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML.Find a live event near you!Please enter your ZIP codeCan’t make it to a live…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Join our upcoming broadcast to learn more about a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+. https://t.co/RlyqNmSMTM Review dosage, administration considerations, and drug interactions. Please see Full Prescribing Information… https://t.co/IBAMZzpqE8 https://t.co/eni3ZCtPtp
-
-
Mashup Score: 0Learn more about VANFLYTA: A treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+ - 12 month(s) ago
Use the zip code search below to find a live location, or register to attend our upcoming broadcast virtually where we explore efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML.Find a live event near you!Please enter your ZIP codeCan’t make it to a live…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Join our upcoming broadcast to learn more about a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+. https://t.co/RlyqNmSMTM Review dosage, administration considerations, and drug interactions. Please see Full Prescribing Information… https://t.co/IBAMZzpqE8 https://t.co/eni3ZCtPtp
-
-
Mashup Score: 0Learn more about VANFLYTA: A treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+ - 12 month(s) ago
Use the zip code search below to find a live location, or register to attend our upcoming broadcast virtually where we explore efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML.Find a live event near you!Please enter your ZIP codeCan’t make it to a live…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Join our upcoming broadcast to learn more about a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+. https://t.co/RlyqNmSMTM Review dosage, administration considerations, and drug interactions. Please see Full Prescribing Information… https://t.co/IBAMZzpqE8 https://t.co/eni3ZCtPtp
-
-
Mashup Score: 0Learn more about VANFLYTA: A treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+ - 12 month(s) ago
Use the zip code search below to find a live location, or register to attend our upcoming broadcast virtually where we explore efficacy and safety results from QuANTUM-First, which was a phase 3, randomized, double-blind, placebo-controlled trial exploring VANFLYTA in patients with newly diagnosed FLT3-ITD+ AML.Find a live event near you!Please enter your ZIP codeCan’t make it to a live…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Join our upcoming broadcast to learn more about a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+. https://t.co/RlyqNmSMTM Review dosage, administration considerations, and drug interactions. Please see Full Prescribing Information… https://t.co/IBAMZzpqE8 https://t.co/eni3ZCtPtp
-
-
Mashup Score: 0OncLive® ASH 2023 On Location - 1 year(s) ago
AdvertisementOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference.Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Register today: OncLive® News Network: On Location at the 2023 American Society of Hematology Annual Meeting! Join us for 3 days of exclusive interviews with top thought leaders: https://t.co/do2mqFZCMJ https://t.co/VukACSiTrL
-
-
Mashup Score: 8OncLive® ASH 2023 On Location - 1 year(s) ago
AdvertisementOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference.Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Register today: OncLive® News Network: On Location at the 2023 American Society of Hematology Annual Meeting! Join us for 3 days of exclusive interviews with top thought leaders: https://t.co/do2mqFZCMJ https://t.co/VukACSiTrL
-
-
Mashup Score: 0OncLive® ASH 2023 On Location - 1 year(s) ago
AdvertisementOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Conference. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the conference.Register NowAlready Registered?First Name*Last Name*Title*Email*PhoneCompany/Institution*City*State*Zip Code*How were you referred to this…
Source: studio.mjhassoc.comCategories: General Medicine News, Onc News and JournalsTweet-
Register today: OncLive® News Network: On Location at the 2023 American Society of Hematology Annual Meeting! Join us for 3 days of exclusive interviews with top thought leaders: https://t.co/do2mqFZCMJ https://t.co/VukACSiTrL
-
Join our upcoming broadcast to learn more about a treatment option for eligible adult patients with newly diagnosed AML that is FLT3-ITD+. https://t.co/RlyqNmSMTM Review dosage, administration considerations, and drug interactions. Please see Full Prescribing Information… https://t.co/IBAMZzpqE8 https://t.co/eni3ZCtPtp